Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25337277 | 1.00 | MAPT (0.46) | MAPTHPGDCYP1A2CYP2C19ALOX12 | |
| SCHEMBL31118999 | 0.94 | MAPT (0.49) | MAPTHPGDCYP1A2CYP2C19ALOX12 | |
| SCHEMBL25981191 | 0.94 | MAPT (0.49) | MAPTHPGDCYP1A2CYP2C19ALOX12 | |
| SCHEMBL25338219 | 0.82 | ESRRA (0.41) | — | |
| SCHEMBL18690489 | 0.75 | AAK1 (0.39) | MAPTALDH1A1HTTLMNAPOLB | |
| SCHEMBL25981190 | 0.75 | ESRRA (0.43) | MAPTHPGDALDH1A1RAB9ANPC1 | |
| SCHEMBL6624771 | 0.73 | MAPT (0.59) | MAPTHPGDCYP1A2CYP2C19ALOX12 | |
| SCHEMBL8837891 | 0.73 | MAPT (0.67) | MAPTHPGDCYP1A2CYP2C19ALOX12 | |
| SCHEMBL8837893 | 0.73 | MAPT (0.67) | MAPTHPGDCYP1A2CYP2C19ALOX12 | |
| SCHEMBL8161148 | 0.72 | MAPT (0.54) | MAPTHPGDCYP1A2CYP2C19ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208913-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2023150197-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208913-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | AHR, ARNT, NR1H2 | MAPT 1282/4885HPGD 404/4885CYP1A2 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.